Vaccine Info

HGCO19 COVID-19 Vaccine

Authored by
Staff
Last reviewed
April 20, 2021
Fact checked by
Danielle Reiter, RN
Share

HGCO19 COVID-19 Vaccine Description

HGCO19 COVID-19 Vaccine is India's first indigenous messenger RNA (mRNA) vaccine. 

mRNA vaccines carry the molecular instructions to make the protein in the body through a synthetic RNA of the targeted virus. The host body uses this to produce the viral protein that is recognized by the immune system, thereby making the body ready to fight against the disease.

The mRNA vaccine technology is synthetic in nature and is being used for the first time ever to combat any disease.

HGCO19 vaccine candidate contains a short, synthetic version encoding the spike protein (antigen) of the novel coronavirus, SARS-CoV-2, reported to interact with receptors on host cells.

When the vaccine is injected into the body the synthetic mRNA is taken to muscle cells where it instructs cells to make numerous copies of mRNA and copies of the antigen. 

HGCO19 COVID-19 Vaccine Indication

HGCO19 COVID-19 Vaccine is indicated to prevent COVID-19 disease, which is caused by the SARS-CoV-2 virus.

HGCO19 COVID-19 Vaccine News

April 12, 2021 - Gennova Biopharma is developing India's first indigenous mRNA COVID-19 vaccine and will receive government funding upon successful completion of its Phase 1 clinical trial.

HGCO19 COVID-19 Vaccine Clinical Trial

The Phase 1 clinical trial to assess the safety and immunogenicity of the vaccine candidate HGCO19 is to begin soon at two sites, Pune and Kolhapur.

This Phase-1 study will enroll 120 healthy participants in the age group of 18-70 years soon. In Phase II, it will enroll approximately 400-500 patients.

Clinical Trials

No clinical trials found